Disruption caused by chimeric antigen receptor T-cell (CAR T) therapy, a type of cell and gene therapy, to standard business models in the life sciences industry
At a recent WSJ Future of Health forum, Ash Shehata, National Healthcare and Life Sciences lead spoke about Deglobalization.
Check in to read insights on how new technologies are transforming the industry.
Growth strategies for turbulent times
The KPMG 2022 Healthcare and Life Sciences Investment Outlook video provides insights to investors on nine industry subsectors.
KPMG helps forge a path through the chaos of COVID
Failing to resume clinical trials could present as many risks to certain patients as COVID-19